CytoDyn Inc.

  • Home
  • About CytoDyn
    • Overview
    • Our Mission
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
    • Join our Team
  • Publications & Posters
  • Newsroom
    • Press Releases
  • Investors
    • Overview
    • Investor FAQs
    • Investor Update Calls
    • Annual Meeting of Stockholders
    • Warrant Exercise Inquiries
    • Restricted Stock Inquiries
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Publications & Posters

  • All
  • COVID-19
  • HIV
  • Oncology
  • GvHD
Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Mar 16, 2021
COVID-19
Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Jan 23, 2021
Oncology
Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab

Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab

Dec 30, 2020
COVID-19
International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Oct 30, 2020
COVID-19
Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab

Oct 20, 2020
COVID-19
National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice

Feb 24, 2018
GvHD
Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

Jul 20, 2010
HIV
RSS
  • « Previous
  • 1
  • 2
© 2025 CytoDyn Inc. All Rights Reserved.
Privacy Policy Legal Notice & Disclaimer Forward-Looking Statement Disclosure Sitemap